France's Transgene H1 operating income falls on lower tax credit

Transgene SA

24/09/2026 16:56

Overview
France biotech firm's H1 2026 operating income declined yr/yr, mainly due to lower research tax credit
Net loss for H1 2026 narrowed compared to prior year
Company ended H1 2026 with €92.8 mln in cash, funded until early 2028

Outlook
Transgene expects topline results from TG4050 Phase 2 trial by end of Q1 2028
Company anticipates first immunological data from TG4050 Phase 2 in H2 2026
Transgene says it has sufficient cash to fund operations until early 2028

Result Drivers
PIPELINE PROGRESS - Co said publication of TG4050 Phase 1 data, completion of Phase 2 randomization, and initiation of TG4070 Phase 1 trial were key operational milestones
MANUFACTURING ADVANCES - Co said cell-line based manufacturing and proprietary AI tools support scalability and precision in vaccine development

Company press release: ID:nGNE1NppCp

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Operating Income
 
EUR 3 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Transgene SA is €1.60, about 88.9% above its September 23 closing price of €0.85

Reuters Recommended Reads
Sept 21 - France's Abivax H1 net loss widens on higher expenses driven by clinical programs
Sept 23 - France's ABIONYX Pharma H1 net loss widens as financial expenses rise
Sept 22 - European drugmakers call for faster trials, more spending to compete with US, China

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)